Valuation: Resverlogix Corp.

Market Cap 21.81M 15.37M 13.48M 12.42M 11.63M 1.45B 22.26M 149M 57.78M 717M 57.72M 56.46M 2.49B P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 108M 75.84M 66.49M 61.29M 57.38M 7.15B 110M 737M 285M 3.54B 285M 279M 12.26B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.39%
Yield 2024 *
-
Yield 2025 -
1 day-5.26%
Current month-5.26%
1 month-5.26%
3 months-21.74%
Current year-10.00%
1 week 0.09
Extreme 0.09
0.1
1 month 0.09
Extreme 0.09
0.1
Current year 0.08
Extreme 0.085
0.14
1 year 0.04
Extreme 0.04
0.3
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.9
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 2003-04-24
Director of Finance/CFO 78 2009-10-28
Chief Tech/Sci/R&D Officer - 2022-08-14
Director TitleAgeSince
Chairman - 2016-04-03
Director/Board Member 56 2009-10-14
Director/Board Member 66 2010-09-28
Date Insider Type Main position Quantity % Market Cap.
May. 03Option

Chief Financial Officer

300,000 0.0949%
May. 03Option

Chief Financial Officer

300,000 0.0949%
Mar. 05Option

Chief Financial Officer

62,500 0.0217%
Change 5-day change 1-year change 3-year change Capi.($)
-5.26%0.00%+125.00%-10.00% 21.81M
+0.33%+1.37%+64.03%+119.11% 55.63B
+0.82%+15.05%+79.93%+84.34% 52.25B
+1.36%+0.36%-14.06%-14.69% 23.07B
-1.04%+7.91%+1.61%+419.24% 22.41B
-0.18%+7.20%+32.16%-14.07% 17.32B
-1.10%+4.00%+28.70%-34.51% 15.94B
-3.35%+8.96%+132.20%+290.18% 13.47B
+2.89%+5.51%+27.11%+181.45% 13.77B
+1.31%+0.53%+28.62% - 12.43B
Average -0.42%+4.30%+50.53%+113.45% 22.63B
Weighted average by Cap. +0.26%+5.13%+48.50%+120.16%

Financials

2024 2025
Net sales - -
Net income -7.64M -5.38M -4.72M -4.35M -4.07M -508M -7.79M -52.27M -20.23M -251M -20.21M -19.76M -870M -7.77M -5.47M -4.8M -4.42M -4.14M -516M -7.93M -53.18M -20.58M -255M -20.56M -20.11M -885M
Net Debt 81.87M 57.7M 50.59M 46.64M 43.66M 5.44B 83.57M 561M 217M 2.69B 217M 212M 9.33B 85.79M 60.46M 53.02M 48.87M 45.75M 5.7B 87.57M 587M 227M 2.82B 227M 222M 9.77B
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
26-06-26 CA$0.0900 -5.26% 21,080
26-06-25 CA$0.0950 +5.56% 1,000
26-06-24 CA$0.0900 0.00% 52,000
26-06-23 CA$0.0900 -5.26% 38,000
26-06-22 CA$0.0950 +5.56% 2,100